Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811272 · ClinicalTrials.gov registry record · Phase 2
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
A Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06811272 is a Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06811272, a Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Epcoritamab
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Newton-Wellesley Hospital - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06811272
The ClinicalTrials.gov registry entry for NCT06811272 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed Large B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06811272 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06811272 about?
NCT06811272 is a clinical study titled "Outpatient Epcoritamab as 2L in NTE R/R DLBCL". The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
What is the current status of trial NCT06811272?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-06-05. Estimated completion is 2028-10-01.
What conditions does trial NCT06811272 study?
This clinical trial studies the following conditions: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT06811272?
The interventions under investigation include: Epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06811272?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06811272 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Relapsed Large B-cell Lymphoma
All registered trials for this condition
Refractory Large B-cell Lymphoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.